Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Argentina

Argentina

In Argentina, the revenue in the Other Vaccines market is forecasted to reach US$184.40m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 9.95%, leading to a market volume of US$296.30m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, amounting to US$24,730.00m in 2024.
Argentina's growing demand for other vaccines is driven by the government's commitment to expanding the country's immunization program.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Argentina has experienced significant growth in recent years.

Customer preferences: Argentinian customers have shown a growing interest in preventative healthcare measures, including vaccinations. This has led to an increase in demand for Other Vaccines, which cover a range of illnesses beyond the common vaccines for flu and childhood diseases.

Trends in the market: One of the key trends in the Other Vaccines market in Argentina is the increasing availability of vaccines for diseases such as meningitis, pneumonia, and hepatitis. As these illnesses become more prevalent in the country, there is a growing need for preventative measures. Additionally, there has been a rise in medical tourism, with foreigners seeking out vaccinations that are not available in their home countries.

Local special circumstances: Argentina has a large population of expats and immigrants, many of whom come from countries with different vaccination schedules and requirements. This has led to a demand for vaccines that may not be commonly used in Argentina. Additionally, the country has a high incidence of certain illnesses, such as dengue fever and yellow fever, which has led to an increased need for preventative measures.

Underlying macroeconomic factors: Argentina has experienced economic instability in recent years, which has led to a rise in healthcare costs. This has made preventative measures, such as vaccinations, more appealing to consumers who are looking to avoid costly medical bills. Additionally, the government has made efforts to increase access to healthcare across the country, which has led to a larger market for preventative healthcare measures.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.